Nachrichten zur CRISPR Therapeutics AG Aktie

Zuger Crispr Therapeutics mit hohem Verlust im Jahr 2022

Im letzten Geschäftsjahr schrieb das Biotechunternehmen ein Minus von 650 Millionen Dollar. Das schwache Ergebnis hatte sich abgezeichnet....…

Crispr Therapeutics mit hohem Verlust im Jahr 2022

Biotechnologie - Das an der Nasdaq kotierte Biotechunternehmen Crispr Therapeutics mit Sitz in Zug hat das Geschäftsjahr 2022 in den roten…

CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Misses Revenue Estimates

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 39.22% and 99.95%, respectively, for the quarter ended December 2022.…

CRISPR Therapeutics GAAP EPS of -$1.41 beats by $0.90

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K CRISPR Therapeutics AG For: Feb 21

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

-Regulatory submissions complete for exagamglogene autotemcel (exa-cel) in Europe for transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD); U.S.…

Beat the Dow Jones With CRISPR Therapeutics Stock

If approved, CRISPRs first product may deliver blockbuster sales....…

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Markets: What You Should Know

CRISPR Therapeutics AG (CRSP) closed at $50.87 in the latest trading session, marking a -1.24% move from the prior day....…

Could CRISPR Therapeutics Stock Help You Become a Millionaire?

The gene-editing business has loads of potential, but is it enough to make you rich?...…

Better Bull Market Buy: CRISPR Therapeutics or Vertex Pharmaceuticals?

Both stocks should be winners if gene-editing therapy exa-cel wins regulatory approvals....…

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company…

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Markets: What You Should Know

CRISPR Therapeutics AG (CRSP) closed at $55.27 in the latest trading session, marking a -1.51% move from the prior day....…

Strength Seen in CRISPR Therapeutics AG (CRSP): Can Its 7.2% Jump Turn into More Strength?

CRISPR Therapeutics AG (CRSP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate…

Insiderhandel: Chief Executive Officer verkauft Aktien von Crispr Therapeutics im Wert von 1.286.798$

Kulkarni, Samarth - Vorstand - Tag der Transaktion: 2023-01-27...…

3 Things About CRISPR Therapeutics That Smart Investors Know

The gene-therapy specialists near-term outlook is quite bullish....…

Global CRISPR Technology Research Report Report 2023-2027 Featuring Major Players - CRISPR Therapeutics, GenScript, Lonza Group, PerkinElmer, & Thermo Fisher Scientific

DUBLIN, Jan. 25, 2023 /PRNewswire/ -- The "CRISPR Technology: Global Markets" report has been added to ResearchAndMarkets.coms offering. A $9.2…

Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics?

Last year paved the way for a potential breakthrough this year for both gene-editing biotech companies....…

CRISPR Therapeutics Stock: Bull vs. Bear

Should investors buy this risky biotech stock as the company moves toward bringing its first major treatment to market?...…

CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $49.94, marking a +0.56% move from the previous day....…

More Likely to 5X First: CRISPR Therapeutics vs. InMode

These two companies are in very different situations but could generate significant returns for investors....…

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Markets: What You Should Know

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $46.68, moving -1.12% from the previous trading session....…

Insiderhandel: Chief Executive Officer verkauft Aktien von Crispr Therapeutics im Wert von 1.023.290$

Kulkarni, Samarth - Vorstand - Tag der Transaktion: 2022-12-28...…

Could CRISPR Therapeutics Help You Become a Millionaire?

The gene-editing stock still has plenty of promise....…

CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development

ZUG, Switzerland and BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on…

CRISPR Therapeutics Provides Update on Its Ongoing Phase 1 CARBON™ Trial of CTX110®

-Update provided for both Part A (single dose with optional re-dosing) and Part B (consolidation dosing) of the Phase 1…

Is CRISPR Therapeutics a Buy?

A strong cash position could offset some of the near-term risks that come with owning the biotech....…

Why Is CRISPR Therapeutics AG (CRSP) Up 0.2% Since Last Earnings Report?

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings…

Insiderhandel: Chief Executive Officer verkauft Aktien von Crispr Therapeutics im Wert von 1.350.827$

Kulkarni, Samarth - Vorstand - Tag der Transaktion: 2022-11-28...…

Biotechnologie: Crispr/Cas: Erste Therapie auf Basis der Genschere ist auf dem Weg zur Zulassung

Mit dem Produkt wollen die Biotechfirmen Vertex und Crispr Therapeutics eine seltene Erbkrankheit heilen. Es könnte den Weg für weitere…

Crispr Therapeutics Stock: Bull vs. Bear

Crispr shares have fallen about 20% so far this year....…

CRISPR Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

ZUG, Switzerland and BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused…

Why Shares of CRISPR Therapeutics Dropped 19.9% in October

Several factors weighed on the gene-editing biotech stocks last month....…

CRISPR Therapeutics Announces Poster Presentation on CTX110® at the American Society of Hematology (ASH) 2022 Annual Meeting

ZUG, Switzerland and BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused…

dpa-AFX ProFeed